November, 2024
November 2024
M T W T F S S
 123
45678910
11121314151617
18192021222324
252627282930  
Sitravatinib/Ipi/Niv as first line treatment for advanced RCC
Nov 12, 2024, 18:01

Sitravatinib/Ipi/Niv as first line treatment for advanced RCC

Qian Janie Qin, Assistant Professor at UT Southwestern Medical Center, shared a recent article by Jose A. Karam on X:

Dr. Pavlos Msaouel discussing Sitravatinib/Ipi/Niv in 1L advanced RCC- efficacy seen, however significant toxicity.

Tumor cell-spc transcriptomic signature identified& may link to resistance.

Role of triplet treatment remains to be defined, and deep dive correlatives may offer insights.”

Sitravatinib

Title: Phase II trial of neoadjuvant sitravatinib plus nivolumab in patients undergoing nephrectomy for locally advanced clear cell renal cell carcinoma

Authors: Jose A. Karam, Pavlos Msaouel, Cara L. Haymaker, Surena F. Matin, Matthew T. Campbell, Amado J. Zurita, Amishi Y. Shah, Ignacio I. Wistuba, Enrica Marmonti, Dzifa Y. Duose, Edwin R. Parra, Luisa Maren Solis Soto, Caddie Laberiano-Fernandez, Marisa Lozano, Alice Abraham, Max Hallin, Curtis D. Chin, Peter Olson, Hirak Der-Torossian, Xiaohong Yan, Nizar M. Tannir and Christopher G. Wood

Sitravatinib